Drug Profile
ATAF 11
Alternative Names: ATAF-11Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Apcegen Technologies
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Rheumatoid arthritis in India (unspecified route) (Apcegen Technologies pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Rheumatoid arthritis in India
- 17 Aug 2016 Preclinical trials in Rheumatoid arthritis in India (unspecified route)